Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.3%

1 terminated/withdrawn out of 16 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

44%

7 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(33.3%)
Phase 2
5(33.3%)
Phase 1
3(20.0%)
Phase 3
2(13.3%)
15Total
Phase 4(5)
Phase 2(5)
Phase 1(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT02145377Phase 2Completed

PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Role: collaborator

NCT01524640Phase 4Completed

Bridging Study for Killed Oral Cholera Vaccine in Ethiopia

Role: collaborator

NCT00548054Phase 2Unknown

Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants

Role: collaborator

NCT00289224Phase 3Completed

Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Role: collaborator

NCT00760825Phase 4Completed

A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children

Role: collaborator

NCT01233362Phase 2Completed

Study of Alternative Vaccination Schedule of Oral Cholera Vaccine

Role: collaborator

NCT01365442Completed

Pilot Introduction of Oral Cholera Vaccine in Orissa, India

Role: collaborator

NCT01091298Phase 1Completed

A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers

Role: lead

NCT01061658Phase 1Unknown

Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine

Role: lead

NCT00776165Phase 3Completed

Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)

Role: lead

NCT00757926Phase 1Withdrawn

Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants

Role: lead

NCT00419133Phase 2Completed

Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine

Role: collaborator

NCT00674908Phase 4Completed

Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine

Role: lead

NCT00617812Phase 4Completed

Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine

Role: lead

NCT00877357Phase 4Unknown

Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine

Role: lead

NCT00119197Phase 2Completed

Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata

Role: collaborator

All 16 trials loaded